Daiichi Sankyo Positions Its Covid Vaccine as a Booster in Japan
- Clearance of the first home-grown mRNA shot expected in 2022
- Availability may come after most people are already vaccinated
This article is for subscribers only.
We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
Daiichi Sankyo Co.’s home-grown Covid vaccine, a cutting-edge mRNA shot that’s on the cusp of its final clinical trials, could be used mainly as a booster starting next year for people who have already been immunized, the Japanese drugmaker said.